Cas 1227094-79-2,1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea

1227094-79-2

Post Buying Request

Basic information

Product Name: 1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea
Synonyms: 1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea
CAS NO:1227094-79-2
Molecular Formula:
Molecular Weight: 393.316
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea(CAS DataBase Reference)
NIST Chemistry Reference: 1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea(1227094-79-2)
EPA Substance Registry System: 1-(3,4-dichIorobenzyI)-3-(2-(8-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)urea(1227094-79-2)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1227094-79-2(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1227094-79-2 Suppliers

Recommended suppliers

1227094-79-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1227094-79-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,0,9 and 4 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1227094-79:
(9*1)+(8*2)+(7*2)+(6*7)+(5*0)+(4*9)+(3*4)+(2*7)+(1*9)=152
152 % 10 = 2
So 1227094-79-2 is a valid CAS Registry Number.

1227094-79-2Upstream product

1227094-79-2Downstream Products

1227094-79-2Relevant academic research and scientific papers

COMPOUNDS USEFUL AS HIV BLOCKERS

-

Page/Page column 102-103, (2010/06/15)

The present invention relates to a compound having the general Formula (I): wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment or prevention of chemokine-mediated disorders such as HIV infection.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1227094-79-2